This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koukourakis, M. I. Articles by Harris, A. L. Search for Related Content PubMed PubMed Citation Articles by Koukourakis, M. I. Articles by Harris, A. L.

Angiogenesis, Thymidine Phosphorylase, and Resistance of Squamous Cell Head and Neck Cancer to Cytotoxic and Radiation Therapy¹

Tumour and Angiogenesis Research Group, Department of Radiotherapy and Oncology, Medical School, University of Thessalia, Larissa 41222, Greece [M. I. K.]; Department of Pathology, Democritus University of Thrace, Alexandroupolis 68100, Greece [A. G., E. S.]; Department of Medical Oncology, Hellenic Co-operative Oncology Group, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki 54006, Greece [G. F.]; Department of Cellular Science and Imperial Cancer Research Fund Medical Oncology Unit, Oxford Radcliffe Hospital, Headington, Oxford OX3 7LJ, United Kingdom [K. C. G., A. L. H.]

Thymidine phosphorylase (TP), an enzyme involved in the thymidine synthesis and degradation, has been shown to promote tumor angiogenesis. Both TP expression and tumor vascularization are putative postoperative prognostic markers of cancer. Because of its bifunctional role, TP may have interactions with cytotoxic drugs or radiation via pathways requiring thymidine or prodrug activation. The microvessel score and TP expression were examined immunohistochemically on paraffin-embedded bioptical material from 94 locally advanced squamous cell head and neck carcinomas. All patients were treated with conventionally fractionated radiotherapy combined with induction (platinum- and 5-fluorouracil-based) or concurrent platinum chemotherapy. The follow-up of patients ranged from 6 to 108 months (median, 48 months). Nuclear TP expression was significantly associated with increased microvessel score (P < 0.0001, r = 0.45). A low percentage of cancer cells with nuclear TP expression in pretreatment biopsies was associated with a high rate of CR after combined chemoradiotherapy (P = 0.006) and induction chemotherapy (0.01). A better local relapse-free and overall survival was also observed in these patients (P = 0.001 and P = 0.0005, respectively). Biospies on the day after the delivery of 20 Gy of conventionally fractionated radiotherapy showed residual cancer cell nests, frequently of high vascularization and of intense nuclear TP reactivity. It is concluded that thymidine phosphorylase is associated with angiogenesis, with resistance to radiotherapy and cytotoxic therapy, and with poorer survival in squamous cell head and neck cancer. A strong rationale is provided for subsequent clinical trials of concurrent radiotherapy and chemotherapy with antiangiogenic agents or with specific TP inhibitors.

This article has been cited by other articles:

				I. Ganly, S. Talbot, D. Carlson, A. Viale, E. Maghami, I. Osman, E. Sherman, D. Pfister, S. Chuai, A. R. Shaha, et al. Identification of Angiogenesis/Metastases Genes Predicting Chemoradiotherapy Response in Patients With Laryngopharyngeal Carcinoma J. Clin. Oncol., April 10, 2007; 25(11): 1369 - 1376. [Abstract] [Full Text] [PDF]

				H. Tsuzuki, H. Sunaga, T. Ito, N. Narita, C. Sugimoto, and S. Fujieda Reliability of Platelet-Derived Endothelial Cell Growth Factor as a Prognostic Factor for Oral and Oropharyngeal Carcinomas Arch Otolaryngol Head Neck Surg, December 1, 2005; 131(12): 1071 - 1078. [Abstract] [Full Text] [PDF]

				E. Hanna, M. Alexiou, J. Morgan, J. Badley, A. M. Maddox, J. Penagaricano, C.-Y. Fan, R. Breau, and J. Suen Intensive Chemoradiotherapy as a Primary Treatment for Organ Preservation in Patients With Advanced Cancer of the Head and Neck: Efficacy, Toxic Effects, and Limitations Arch Otolaryngol Head Neck Surg, July 1, 2004; 130(7): 861 - 867. [Abstract] [Full Text] [PDF]

				E. Sivridis, A. Giatromanolaki, and M. I. Koukourakis "Stromatogenesis" and Tumor Progression International Journal of Surgical Pathology, January 1, 2004; 12(1): 1 - 9. [Abstract] [PDF]

				K. A. Hotchkiss, A. W. Ashton, R. S. Klein, M. L. Lenzi, G. H. Zhu, and E. L. Schwartz Mechanisms by Which Tumor Cells and Monocytes Expressing the Angiogenic Factor Thymidine Phosphorylase Mediate Human Endothelial Cell Migration Cancer Res., January 15, 2003; 63(2): 527 - 533. [Abstract] [Full Text] [PDF]

				A. Giatromanolaki, E. Sivridis, C. Simopoulos, A. Polychronidis, K. C. Gatter, A. L. Harris, and M. I. Koukourakis Thymidine Phosphorylase Expression in Gallbladder Adenocarcinomas International Journal of Surgical Pathology, July 1, 2002; 10(3): 181 - 188. [Abstract] [PDF]

				F. Mayer, J. T. Hartmann, J. von Pawel, J. Beck, M. Schroeder, I. Boehlke, L. Kanz, and C. Bokemeyer A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors Ann. Onc., May 1, 2002; 13(5): 755 - 759. [Abstract] [Full Text] [PDF]

				M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. Simopoulos, J. Pastorek, C. C. Wykoff, K. C. Gatter, and A. L. Harris Hypoxia-regulated Carbonic Anhydrase-9 (CA9) Relates to Poor Vascularization and Resistance of Squamous Cell Head and Neck Cancer to Chemoradiotherapy Clin. Cancer Res., November 1, 2001; 7(11): 3399 - 3403. [Abstract] [Full Text] [PDF]